

Oncology & Hematology

Expertise and adeptness for speed and certainty



Aligned for Agility

Caidya delivers peace of mind to biopharma innovators with agility, and trial design and execution that maximizes speed and certainty. We are designed to **adapt and grow** with you as you bring new oncology and hematology treatments to market. Our **distinct global presence** empowers us to rapidly adapt to shifting trial landscapes, supporting global and regional development needs with confidence and speed.



Execution – Partnerships through People

- Preemptively and collaboratively solve issues and reduce risks, maximizing the **speed and certainty** of your trials.
- Tailored strategy, delivery, proactive solutions and **patient recruitment precision** that yields the high-quality data you need for informed decision-making.
- **~60% faster** trial activation-to-close times vs. industry average.
- Global **clinical-phase oncology** delivery across 50+ countries with specialized strength in APAC.



Expertise that Matters

- Early engagement to help refine strategy, improve targeting, and **accelerate delivery**.
- Our experience in – and insights for – clinical phase oncology and hematology trials help **streamline your path** from inception to market.
- Practical tech solutions for **patient recruitment precision** drive the identification and enrollment of the right patients to generate necessary data.



Our People

Our integrated medical, scientific, and operational teams engage early and often with the skill to **navigate critical inflection points** across the development lifecycle.

With 97% of PMs experienced in oncology and nearly 30% in hematology, we deliver with confidence across all phases.

Therapeutic Leadership:

Adam Callahan, MS, MBA, VP Global Therapeutic Area Head, Oncology & Hematology

Adam brings nearly **30 years of experience** and a strong record of building high-performing, global teams that drive clinical programs for regulatory approval and commercialization of therapies. Adam's teams also bring an adeptness in **molecule-to-market strategies** and **operational excellence**. Adam ensures our ability to provide development strategies while delivering exceptional experiences for our clients conducting oncology, hematology and cell and gene therapy studies.



“We work as one team – sharing the hard work and the successes – in the development of a critically important novel therapy for patients with limited options.”

VP of Clinical at a leading precision cancer medicines biopharma



caidya[®]

Adapting at The Speed of Science

Clinipace, Inc. is owned, operated, managed, and controlled by dMedClinical Co. Ltd., a privately held company, whose investors include entities located in the People's Republic of China (PRC), and which may be subject to PRC laws and regulations that differ from those of the United States.

LEARN MORE AT [CAIDYA.COM](https://caidya.com)

caidya[®]